The phase III KEYNOTE-024 trial showed pembrolizumab as new standard first-line treatment in advanced NSCLC with high PD-L1 expression, defined as expression in at least 50% of tumor cells, tumor proportion score (TPS) ≥50%, and absence of EGFR or ALK aberrations [6]. Here, CD274 is linked to non-small cell lung carcinoma.